This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ESMO 2020
Presentations
Enfortumab vedotin | Urothelial Cancer | Abstract 2223
EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
Enfortumab vedotin | Urothelial Cancer | Abstract 2065
Study EV-302: A 3-arm, open-label, randomized phase 3 study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer
Videos
Enfortumab vedotin | Urothelial Cancer | Abstract 2223
EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors